ARA-290 16mg

ARA-290 is a synthetic peptide engineered to mimic the beneficial effects of erythropoietin (EPO) in tissue protection, repair, and anti-inflammatory actions without stimulating red blood cell production. This innovative peptide is designed to harness the healing and regenerative capabilities of the innate repair receptor (IRR), which is activated by EPO and other members of the erythropoietin family, targeting the receptor directly involved in tissue protection and repair.

Unlike traditional EPO, ARA-290 does not lead to an increase in hematocrit or affect blood viscosity, making it a safer alternative for applications requiring tissue repair and anti-inflammatory effects without the risk of thrombosis. This unique characteristic opens up new avenues for the peptide in potentially managing conditions that benefit from its reparative and anti-inflammatory properties, without the complications associated with increased red blood cell counts.

Current areas of research of ARA-290 include promoting nerve regeneration, reducing neuropathic pain, and enhancing recovery from tissue injuries. Its potential in improving the quality of life for individuals suffering from conditions associated with chronic inflammation and nerve damage is of particular interest. The peptide has been studied in the context of diabetic neuropathy, sarcoidosis-related small fibre neuropathy, and other conditions characterized by nerve damage and chronic pain, showing promise in symptom alleviation and functional improvement.

The development of ARA-290 is based on a deep understanding of the molecular pathways involved in tissue repair and inflammation. By targeting the IRR, research is attempting to establish whether ARA-290 may offer a targeted approach to activating the body's natural repair mechanisms, potentially offering benefits in a range of conditions without the side effects associated with other treatments that have broader systemic effects.

In summary, ARA-290 represents a novel approach in the field of regenerative medicine and anti-inflammatory therapy. Its specificity for the IRR, combined with the absence of erythropoietic activity, makes it a promising candidate for further research and application in conditions that would benefit from its unique mechanism of action. As research continues, ARA-290 may offer new hope for patients seeking alternatives to current treatment options for chronic pain, nerve damage, and other related conditions.

Technical details

Synonyms: Cibinetide, ARA-290, PHBSP

Sequence: XEQLERALNSS

IUPAC Condensed: H-Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH

Molecular Weight:  1257.3 g/mol

CAS Number: 1208243-50-8

PubChem CID: 91810664

Further references

PubChem

Stability: Store lyophilised protein at -20°c. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4°c for a limited period of time. The lyophilised protein remains stable until expiry date when stored at -20°c. For more information about storage, click here

Source: Biosynthesis

Reconstitution: Reconstitute with Bacteriostatic Water

Usage: Product is prepared for LABORATORY RESEARCH ONLY. ARA-290 for sale at Pure Peptides UK is limited to scientific research and education only – Only buy ARA-290 if you are a licenced researcher.

* Images for illustration purposes only